Galectin Therapeutics INC

Galectin Therapeutics Inc. announced the conversion of approximately $105.8 million in debt, including principal and accrued interest, into common stock by Chairman Richard E. Uihlein, significantly strengthening its balance sheet.

Galectin Therapeutics announced its first-quarter 2026 financial results, highlighting progress in its belapectin program for MASH cirrhosis and providing a business update.

Galectin Therapeutics announced its 2025 financial results, highlighted progress in its belapectin development program for MASH cirrhosis, and extended its cash runway through April 2027.

Galectin Therapeutics Inc. announced the appointment of internationally recognized neurosurgeon-scientist Dr. Henry Brem as an independent director to its Board of Directors, effective March 12, 2026.

Galectin Therapeutics' Board of Directors approved cash retention bonuses for its Chief Medical Officer and Chief Financial Officer, totaling $450,000.

Galectin Therapeutics Inc. announced the resignation of Marc Rubin from its Board of Directors, effective January 10, 2026.

Galectin Therapeutics reports a narrowed net loss for Q1 2026, driven by decreased R&D spending, while continuing to rely on Chairman's credit lines for liquidity.

Galectin Therapeutics reports mixed NAVIGATE trial results, a significant net loss, and ongoing liquidity concerns, despite securing new related-party financing.

Galectin Therapeutics reported a reduced net loss in Q2 2025, driven by lower R&D expenses, but faces ongoing liquidity challenges and relies on related-party financing.

Galectin Therapeutics reports its Q1 2025 financial results and continues to analyze data from the NAVIGATE clinical trial for belapectin.

Galectin Therapeutics' Q3 2024 report highlights ongoing clinical trials, a recent $6 million line of credit, and a cash runway extending to approximately May 2025.

Galectin Therapeutics reported its financial results for the second quarter of 2024 and provided an update on its clinical programs, including the anticipated interim analysis of its NAVIGATE trial.

Galectin Therapeutics reports 2025 annual results, highlighting mixed NAVIGATE trial outcomes for belapectin in MASH cirrhosis and ongoing financing needs.

Galectin Therapeutics' 10-K filing details the NAVIGATE trial results, ongoing data analysis, financial position, and future strategies for its lead drug candidate, belapectin, in fibrotic diseases and cancer.

Galectin Therapeutics extends warrant expiration dates and files its annual report, detailing financial results and strategic updates.

Richard E Uihlein, a Director and 10% owner of Galectin Therapeutics Inc, reported multiple transactions in common stock on July 31, 2026.

Khurram Jamil, Chief Medical Officer of Galectin Therapeutics Inc, sold 16,250 shares of common stock on July 14, 2026 for $5.13 per share.

Galectin Therapeutics Director Harold Shlevin executed trades under a pre-arranged 10b5-1 plan, selling shares and exercising stock options.

Galectin Therapeutics Chief Medical Officer Jamil Khurram reported transactions involving the sale of common stock and the exercise of stock options under a pre-arranged trading plan.

Galectin Therapeutics reports that Chief Medical Officer Jamil Khurram sold 7,557 shares of common stock under a pre-arranged trading plan.

Chief Medical Officer Jamil Khurram exercised 568 stock options and sold the resulting shares under a Rule 10b5-1 plan.

Galectin Therapeutics Inc. has filed definitive additional proxy materials with the SEC.

Galectin Therapeutics Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 3, 2025, to vote on director elections, executive compensation, auditor ratification, and other business.

Galectin Therapeutics Inc. has filed its definitive proxy statement with the Securities and Exchange Commission.

Galectin Therapeutics will hold its 2024 annual meeting of stockholders virtually on January 23, 2025, to elect directors and ratify the appointment of its independent auditor.

Richard E. Uihlein has significantly increased his beneficial ownership in Galectin Therapeutics Inc. to 49.3% through debt conversion, raising questions about control and future strategy.